Professor of Medicine
Campus mail
03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
Phone
(919) 684-3262
Email address
manal.abdelmalek@duke.edu
My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.
Education and Training
- Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
- Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
- M.D., University of Missouri Kansas City, School of Medicine, 1992
Grants
- Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (ALPINE 4)
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- TERN101-201 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients
- A multidisciplinary study of biological disparities in NASH progression and response to statins to inform personalized liver cancer chemoprevention in NAFLD
- A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
- A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
- ARMOR
- Celgene CC-90001 NASH-001
- Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis
- Duke CTSA (TL1)
- VK2809 A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoholic
- A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis.
- Is Heart Failure with Preserved Edection Fraction the Symptomatic Manifestation of Liver Disease
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)
- Intercept 747-303 - A phase 3 double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of Obeticholic acid in subjects with Nonalcoholic Steatohepatitis.
- Genentech GC41003
- A Randomized, Open-label, Phase 1b Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Signals of DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
- A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in adults with nonalcoholic steatohepatitis (NASH) and Compensated Liver Cirrhosis
- A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in adults with nonalcoholic steatohepatitis (NASH) and Stage 3 liver fibrosis
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
- Inventiva IVA337
- NGM282 18-0108
- A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
- Genfit GFT505-315-1 NASH - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy adn Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
- Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH)
- Progenity PRO-121-NAFLD - EVALUATION OF THE SIGNIFICANCE OF CELL FREE DNA AND EPIGENETIC MARKERS AS PREDICTIVE FACTORS FOR NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
- A randomized, double-blind, placebo-controlled, parallel group trial to assess the efficacy and safety of PXL770 versus placebo after 12 weeks of treatment in patients with Nonalcoholic Fatty Liver Disease (NAFLD) with or without type 2 diabetes
- Novartis LJC242A2201J